Medical Advisors

Aliya Khan is a Professor of Clinical Medicine, Divisions of Endocrinology and Metabolism and Geriatrics at McMaster University and Director of the Calcium Disorders Clinic at McMaster University Medical Centre. She is also the Director of the Fellowship program in Metabolic Bone Disease at McMaster University.

She graduated from the University of Ottawa Medical School with Honors at the age of 22 in the top quarter of her class. She trained in Internal Medicine, Geriatric Medicine and Endocrinology at the University of Toronto and also completed a research fellowship in Calcium and Metabolic Bone disorders at the University of Toronto.

She has over 200 scientific publications on osteoporosis and parathyroid disease as well as numerous book chapters. She is the Editor of the Handbook of Parathyroid Diseases as well as the Co-Editor of the Textbook Bone Metabolism, Parathyroid Gland and Calciotropic Hormones.

Dr. Khan is a member of the Canadian Society of Endocrinology and Metabolism Guidelines committee. She is the founding co-chair of Canadian Endocrine Update. Dr. Khan serves as a peer reviewer for the College of Physicians and Surgeons of Ontario for Endocrinology and Metabolism. She led the development of point of care quality improvement tools for the diagnosis and management of endocrine disorders.

Dr. Khan co-chaired the 3rd and 4th International Workshops on Primary Hyperparathyroidism proceedings published in JCEM in 2009 and 2014, respectively. Dr. Khan led the development of the international standards of care for hypoPARAthyroidism published in 2019.

Dr. Khan led the 1st international study on the use of alendronate in primary hyperparathyroidism as well as the phase 3 trial on the use of cinacalcet in primary hyperparathyroidism. She is currently investigating the use of various PTH molecules in the management of hypoPARAthyroidism in phase 1 and phase 2 clinical trials. She is the principal investigator of the Canadian National HypoPARAthyroidism Registry. She has been involved as a national co-investigator in evaluating bisphosphonates, teriparatide, raloxifene, denosumab, romosozumab as well as abaloparatide in the management of osteoporosis.

Dr. Khan led the development of the Canadian position paper on the diagnosis and management of hypophosphatasia. Dr Khan is the Chair of the Rapid Response Committee of Osteoporosis Canada as well as the Co-chair of the Knowledge Translation committee of Osteoporosis Canada. She is a Scientific Advisor of the International Osteoporosis Foundation and Chair of the International Osteonecrosis of the Jaw Task Force. She led the development of the first international position paper on the diagnosis, prevention, and management of osteonecrosis of the jaw published in 2015 in JBMR.

She formed the Canadian Panel of the International Society of Clinical Densitometry (ISCD) and was a board member of the ISCD as well as the past Chair of the Credentials committee of the ISCD. She led the development of the Canadian Standards for the diagnosis of osteoporosis in men, women, and children.

In 2019 Dr. Khan was asked to serve as the Canadian Ambassador for the American Society of Bone and Mineral Research. She is also serving on the Professional Practice Committee of the ASBMR.

Dr. Khan has received numerous national and international awards including the International Clinician Instructor of the Year 2011 award by the International Society of Clinical Densitometry. The Queen’s Diamond Jubilee Medal for 2012 for excellence in clinical care, research and teaching as well as the International HypoPARAthyroidism Award for 2014 and the International Osteoporosis Foundation award for publishing excellence in 2017. In 2019 she was recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape. In 2020 Dr. Khan was awarded the Osteoporosis Canada Lindy Fraser Award in recognition of her outstanding contributions to the field of osteoporosis research and education.

Published Papers

Dr. Khan's Website

Lynn A. Kohlmeier, M.D. received her undergraduate degree from Yale University, in New Haven, Connecticut, and her medical degree from Stanford University School of Medicine in Stanford, California. Dr Kohlmeier was a resident in internal medicine at the New England Deaconess Hospital at Harvard Medical School in Boston, Massachusetts, and returned to Stanford for her endocrinology fellowship.

As a Clinical Investigator in the Endocrinology Hypertension Division, Skeletal Health and Osteoporosis at Harvard Medical School, she did her postdoctoral training and received a Young Investigator Award for her work with the calcium-sensing receptor. Dr Kohlmeier is recognized as a national speaker for osteoporosis and rare metabolic bone disease, and continues to give CME and community presentations on parathyroid, thyroid and adrenal disease, testosterone and estrogen replacement, and calcium and vitamin D.

Dr. Kohlmeier is an endocrinologist in Spokane, WA, currently working with rural clinics in Eastern Washington and Northern Idaho. She has organized and moderated the Spokane Bone Club, an annual professional meeting with nationally renown guest speakers, since its beginning in 1999. Dr. Kohlmeier and her DXA technicians founded Strong Start in 2001, and continue to provide quality DXA BMD reports and osteoporosis guidelines for DXA sites throughout the Northwest.

Dr. Kohlmeier's involvement in research studies on bone mineral density, bone quality tests, fracture assessment, and osteoporosis, has resulted in multiple publications. She is a reviewer for the Journal of Clinical Densitometry, Metabolism, and Osteoporosis International, and is an executive board member for Advances in Mineral Metabolism/American Society for Bone and Mineral Research.

Dr Kohlmeier is co-founder and director of the non-profit Strides for Strong Bones, with program coordinator, Marla Emde. Together with the help of many volunteers, they have provided free bone density screening and osteoporosis education to thousands of men and women throughout the Northwest, through local community events and at both the West Plains Wunderwoman Triathlon, TRI and DU it for Strong Bones (2007-2018) and Strides for Strong Bones Awareness Walk (2010-present).

Published Papers

Dr. Kohlmeier’s Website

Michael Mannstadt, MD, is an endocrinologist at Massachusetts General Hospital in Boston. He received his MD from Jena University, Germany. He completed his residency training in Internal Medicine and a clinical fellowship in Endocrinology, Diabetes and Metabolism, at Massachusetts General Hospital. 

Dr. Mannstadt established his laboratory within the Endocrine Unit of Massachusetts General Hospital. His research focuses on parathyroid function and disease including (1) understanding the genetic basis of familial hypoPARAthyroidism; (2) defining the mechanisms by which the newly identified genes and pathways impact parathyroid function; (3) using these insights to improve treatment for parathyroid disorders. His basic research also investigates the transcriptional network of parathyroid cells. His clinical research focuses in particular on hypoPARAthyroidism and his research group analyzed one of the largest patient series in hypoPARAthyroidism. This study reveals significant shortcomings of our current therapy. Recognizing the limitations of current therapies, he became the Principal Investigator of an NIH grant for the development of a long-acting PTH, and is the lead author of the phase 3 clinical trial of PTH(1-84) in hypoPARAthyroidism. He is a Medical Advisor for the HypoPARAthyroid Association and a frequent faculty participant at their annual patient meetings. He has participated in the development of guidelines for the management of hypoPARAthyroidism.

Published Papers

Mishaela Rubin obtained her MD degree at Columbia University’s Vagelos College of Physicians & Surgeons in 1995. She went on to complete her residency in Medicine and her fellowship in Endocrinology at Columbia and has been on the faculty there since 2002. Dr. Rubin also obtained a Master's degree at Columbia’s Mailman School of Public Health in Biostatistics.

She is currently an Associate Professor in the Department of Medicine at Columbia and sees patients and conducts research in the Division of Endocrinology’s Metabolic Bone Disease Unit. Dr. Rubin studies hypoPARAthyroidism and has published studies characterizing the clinical, biochemical and skeletal features of patients with this disease. She has led clinical trials sponsored by the NIH and by industry to treat hypoPARAthyroid patients with parathyroid hormone therapy. She is currently conducting an NIH-funded study to develop a continuous calcium sensor skin patch for hypoPARAthyroid patients. She is also leading an FDA-funded study to investigate the natural history of hypoPARAthyroidism.

Dr. Rubin also studies diabetic bone disease and has conducted studies of the structural, dynamic and material alterations in the skeleton of type 2 diabetes patients. She led an NIH-sponsored clinical trial to investigate the skeletal effects of blocking advanced glycation end product accumulation in postmenopausal women with type 2 diabetes. Dr. Rubin is also focused on bone health in type 1 diabetes patients. She is a co-investigator in the Skeletal Health study of the long-term DCCT/EDIC study of type 1 diabetes patients. She is also leading an NIH-funded study characterizing the longitudinal changes in bone microarchitecture of type 1 diabetes children as they undergo peak bone accrual.

Published Papers

Dolores Shoback is on the faculty of the University of California, San Francisco in the Department of Medicine where she is currently Professor of Medicine and Staff Endocrinologist at the San Francisco Veterans Affairs Medical Center. Her research and clinical interests are in the regulation of parathyroid hormone secretion with specific focus on the role of calcium-sensing receptors in parathyroid cells and osteoblasts. Her clinical activities focus on metabolic bone diseases, parathyroid disorders, and osteoporosis. She has conducted clinical trials on the use of parathyroid hormone in the treatment of hypoPARAthyroidism. She has co-authored over 180 papers, reviews and editorials. She participated in the development of guidelines for the management of hypoPARAthyroidism in adults for the European Society of Endocrinology (2013-2015), the First International Workshop (2016) and the Second International Workshop on HypoPARAthyroidism (2021-22).

Published Papers

Dr. Shoback's Research

Dr. Gafni received her BA from Barnard College and her MD from Temple University. She completed a pediatric residency at the Children's Hospital of Philadelphia followed by a pediatric endocrinology fellowship at the National Institute of Health (NIH), serving as an officer in the Public Health Service from 1996-2002. She subsequently served as an Assistant Professor at the University of Maryland. Dr. Gafni returned to NIH in 2007 as a staff clinician in the National Institute of Dental and Craniofacial Research. She is also faculty in the NIH Pediatric Endocrinology and NIH Inter-institute Adult Endocrinology Training Programs. She is an investigator on several protocols studying and treating patients with endocrine disorders including hypoPARAthyroidism, McCune-Albright Syndrome, hypophosphatemic rickets, hyperphosphatemic familial tumoral calcinosis, generalized arterial calcification of infancy, and other metabolic bone diseases.

Published Papers

Dr. Mark Warren graduated Magna Cum Laude with his BA from Wake Forest University. He earned his medical degree from the University of North Carolina School of Medicine in Chapel Hill. His Residency in Internal Medicine and Fellowship in Endocrinology were completed at the University of Virginia. Dr. Warren is certified by the American board of Internal Medicine and in Endocrinology and Metabolism. He is active in clinical trials and has several publications in medical journals, including New England Journal of Medicine. He joined the practice in 1989.

Research Interests

Dr. Kelly Lauter Roszko’s research interests center around disorders of mineral homeostasis which include diseases of altered FGF23 metabolism and hypoparathyroidism. Her main focus is hyperphosphatemic familial tumoral calcinosis, a disease of FGF23 deficiency resulting in high serum phosphate levels and ectopic calcification. She studies patients with this disease and uses a mouse model to expand understanding of the phenotype, mechanism of disease, and treatment options. She has published numerous manuscripts including those focused on Autosomal Dominant Hypocalcemia (ADH) Type 1 and 2; and she is an investigator on the trials of Encaleret, a calcilytic medication for targeted therapy of ADH1. As a physician-scientist, she is pursuing projects in the basic science and in translational medicine with the goal of bringing new treatments to patients with rare diseases of mineral metabolism.

Biographical Sketch

Dr. Kelly Roszko is an Adult Endocrinologist at the National Institutes of Health. Her interest in bone and mineral metabolism began during her M.D., Ph.D. training at the University of Connecticut. She initially studied hyperparathyroidism and completed her Ph.D. dissertation under the mentorship of Dr. Andrew Arnold, M.D. She then completed internship and residency in Internal Medicine as well as fellowship in Endocrinology at the Massachusetts General Hospital/Harvard Medical School in Boston. There, with the mentorship of Dr. Michael Mannstadt, she focused on Autosomal Dominant Hypocalcemia Type 2 (ADH2), creating a mouse model of the disease and testing treatments. After her fellowship, she joined the faculty at Massachusetts General Hospital before moving to NIH. She is now working in NIDCR’s Skeletal Disorders and Mineral Homeostasis Section, led by Dr. Michael Collins.

Iris Hartley, M.D., is an endocrinologist and clinician investigator in NIH’s Inter-Institute Endocrinology Training Program. Both her research and clinical work focus on rare metabolic bone diseases and disorders of mineral homeostasis. She is particularly interested in studying diseases related to aberrant fibroblast growth factor 23 (FGF23) homeostasis and applying them as tools for developing a broader understanding of FGF23 physiology. She was the lead associate investigator on the National Institute of Dental and Craniofacial Research’s (NIDCR’s) recently closed Single Patient Emergency Use of BGJ398 in the Treatment of Metastatic Phosphaturic Mesenchymal Tumor protocol, and is an associate investigator on NIDCR’s BGJ398 for the Treatment of Tumor-Induced Osteomalacia (18-D-0086) and Evaluation and Treatment of Bone and Mineral Disorders (01-D-0184). Dr. Hartley graduated from the University of Maryland Medical School, where she was inducted into the Alpha Omega Alpha Honor Medical Society. She completed her internal medicine clinical training at the University of Maryland Medical Center, followed by fellowship in adult endocrinology, diabetes, and metabolism at NIH under the mentorship of Dr. Michael T. Collins. She is board certified in internal medicine as well as in endocrinology, diabetes, and metabolism by the American Board of Internal Medicine.